By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Bayer Pharma
AG et al. v. Watson Pharmaceuticals Inc. et al.
1:12-cv-01726;
filed December 18, 2012 in the District Court of Delaware

• Plaintiffs: 
Bayer Pharma AG; Bayer Intellectual Property GMBH; Bayer HealthCare
Pharmaceuticals Inc.
• Defendants: 
Watson Pharmaceuticals Inc.; Watson Laboratories Inc.

Infringement
of U.S. Patent No. 8,071,577 ("Multi-phase Contraceptive Preparation Based
On a Natural Estrogen," issued December 6, 2011) following a Paragraph IV
certification as part of Watson's filing of an ANDA to manufacture a generic
version of Bayer's Natazia® (estradiol valerate and estradiol
valerate/dienogest, used as oral contraception).  View the complaint here.

Life
Technologies Corp. et al. v. Promega Corp.
3:12-cv-02992;
filed December 17, 2012 in the Southern District of California

• Plaintiffs: 
Life Technologies Corp.; Applied Biosystems, LLC
• Defendant: 
Promega Corp.

Declaratory
judgment of non-infringement of U.S. Patent Nos. 5,843,660 ("Multiplex
Amplification of Short Tandem Repeat Loci, issued December 1, 1998), 6,221,598
(same title, issued April 24, 2001), 6,479,235 (same title, issued November 12,
2002), and 7,008,771 (same title, issued March 7, 2006) based on Plaintiff's
anticipated launch of its Authentifiler PCR analysis products.  View the complaint here.

Merz
Pharmaceuticals LLC v. Par Pharmaceutical Inc. et al.
1:12-cv-01723;
filed December 17, 2012 in the District Court of Delaware

• Plaintiff: 
Merz Pharmaceuticals LLC
• Defendants: 
Par Pharmaceutical Inc.; Par Pharmaceutical Companies Inc.

Infringement
of U.S. Patent Nos. 7,638,552 ("Method for Increasing the Bioavailability
of Glycopyrrolate," issued December 19, 2009) and 7,816,396 (same title,
issued October 19, 2010) following a Paragraph IV certification as part of Par's  filing of an ANDA to manufacture a generic
version of Merz's Cubposa® (glycopyrrolate oral solution, used to reduce
chronic severe drooling in patients aged 3 to 16 years with neurologic
conditions associated with problem drooling (e.g. cerebral palsy)).  View the complaint here.

University of
Iowa Research Foundation et al. v. Kappos et al.
1:12-cv-01444;
filed December 14, 2012 in the Eastern District of Virginia

• Plaintiffs: 
University of Iowa Research Foundation; Coley Pharmaceutical GmbH; Ottawa
Hospital Research Institute; Pfizer Inc.
• Defendants: 
David J. Kappos; Office of General Counsel

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,202,688 ("Use of Nucleic Acids
Containing Unmethylated CPG Dinucleotide as an Adjuvant," issued June 19,
2012).  View the complaint here.

Genetic
Technologies Ltd. v. Genelex Corp.
2:12-cv-02190;
filed December 14, 2012 in the Western District of Washington

Infringement
of U.S. Patent No. 5,612,179 ("Intron Sequence Analysis Method for
Detection of Adjacent Locus Alleles as Haplotypes," issued March 18, 1997)
based on Genelex's manufacture, use, sale, and offer for sale of DNA testing
services, including paternity, forensics, and phramacogenetic testing.  View the complaint here.